FDA approves Sancuso for CINV

FDA approved an NDA from ProStrakan (LSE:PSK) for Sancuso to prevent chemotherapy-induced nausea and vomiting (CINV). The company plans to launch the transdermal granisetron patch this year. Sancuso is under review in the EU. On Monday, ProStrakan was up 3.25p to 101.25p. ...